Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.

被引：1
|
作者：
Kalinsky, K.
Sparano, J. A.
Kim, M.
Crew, K. D.
Maurer, M. A.
Taback, B.
Feldman, S. M.
Hibshoosh, H.
Wiechmann, L.
Adelson, K. B.
Hershman, D. L.
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Columbia Univ, New York, NY USA
[4] Columbia Univ, Med Ctr, Div Breast Surg, Dept Surg, New York, NY USA
[5] Montefiore Med Grp, Bronx, NY USA
[6] Mt Sinai Sch Med, Dept Med Oncol, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS147
引用
收藏
页数：1
相关论文
共 50 条
  • [21] MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines
    Almhanna, Khaldoun
    Cubitt, Christopher L.
    Zhang, Shumin
    Kazim, Sabiha
    Husain, Kazim
    Sullivan, Daniel
    Sebti, Said
    Malafa, Mokenge
    CANCER BIOLOGY & THERAPY, 2013, 14 (10) : 932 - 936
  • [22] The Effect of MK-2206, a New AKT Inhibitor on the Gastric Cancer Cells Growth and Enhancement of Chemotherapy
    Jin, Piaopiao
    Cheng, Jianfeng
    Sun, Leimin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S41 - S41
  • [23] SAFETY AND EFFICACY OF MK-8669 (RIDAFOROLIMUS) + MK-2206 (AKT INHIBITOR) IN PATIENTS WITH ADVANCED BREAST CANCER WITH PI3K PATHWAY DEPENDENCE
    Gupta, S.
    Munster, P.
    Hollebecque, A.
    Argiles, G.
    Guren, T.
    Cheng, J.
    Wang, R.
    Swift, A.
    Tosolini, A.
    Piha-Paul, S.
    ANNALS OF ONCOLOGY, 2014, 25 : 25 - 25
  • [24] Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin
    Pant, Alok
    Lee, Irene I.
    Lu, Zhenxiao
    Rueda, Bo R.
    Schink, Julian
    Kim, J. Julie
    PLOS ONE, 2012, 7 (07):
  • [25] Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program
    Gorlick, Richard
    Maris, John M.
    Houghton, Peter J.
    Lock, Richard
    Carol, Hernan
    Kurmasheva, Raushan T.
    Kolb, E. Anders
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Billups, Catherine A.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (03) : 518 - 524
  • [26] In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor
    Lu, Wei
    Defeo-Jones, Debbie
    Davis, Lenora
    Hang, Gaozhen
    Tammam, Jennifer
    Hatch, Harold
    Lutterbach, Bart
    Ware, Christopher
    Haskell, Kathleen
    Drakas, Bob
    Leander, Karen
    Leander, Karen
    Cherrin, Craig
    Watkins, Aubrey
    Hamilton, Kelly
    Sanderson, Philip
    Huber, hans
    Majumder, Pradip
    Pan, Bo-Sheng
    CANCER RESEARCH, 2009, 69
  • [27] A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
    Stover, Elizabeth H.
    Xiong, Niya
    Myers, Andrea P.
    Tayob, Nabihah
    Engvold, Victoria
    Polak, Madeline
    Broaddus, Russell R.
    Makker, Vicky
    Drapkin, Ronny
    Liu, Joyce F.
    Horowitz, Neil S.
    Meric-Bernstam, Funda
    Aghajanian, Carol
    Coleman, Robert L.
    Mills, Gordon B.
    Cantley, Lewis C.
    Matulonis, Ursula A.
    Westin, Shannon N.
    Konstantinopoulos, Panagiotis A.
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 40
  • [28] The AKT inhibitor MK-2206 promotes apoptosis in acute myeloid leukemia cells
    Ruvolo, Peter P.
    Zeng, Zhihong
    Ruvolo, Vivian R.
    Borthakur, Gautam
    Kornblau, Steven M.
    Andreeff, Michael
    Konopleva, Marina
    CANCER RESEARCH, 2012, 72
  • [29] Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
    Konopleva, Marina Y.
    Walter, Roland B.
    Faderl, Stefan H.
    Jabbour, Elias J.
    Zeng, Zhihong
    Borthakur, Gautam
    Huang, Xuelin
    Kadia, Tapan M.
    Ruvolo, Peter P.
    Feliu, Jennie B.
    Lu, Hongbo
    Debose, LaKiesha
    Burger, Jan A.
    Andreeff, Michael
    Liu, Wenbin
    Baggerly, Keith A.
    Kornblau, Steven M.
    Doyle, L. Austin
    Estey, Elihu H.
    Kantarjian, Hagop M.
    CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2226 - 2235
  • [30] Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer
    Gupta, Shilpa
    Munster, Pamela N.
    Hollebecque, Antoine
    Argues, Guillem
    Dajanl, Olav
    Chang, Jonathan D.
    Swift, Ann M.
    Tosolini, Alessandra
    Piha-Paul, Sarina Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345